Total item
Cart Subtotal
$0.00 - Chenyang He, .et al. Detection of Dabrafenib using Optical Fibre Long Period Grating Sensor Modified with Surface Imprinted Polymers for Dose Detection and Prevention of Cancer Resistance, Clinical and Translational Biophotonics, 2020, TTh3B.2
- Hirosumi Tamura, .et al. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues, Oncol Rep, 2018, Aug; 40(2): 635-646 PMID: 29917168
- Fujita KI, .et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358
- Brittany M. Duggan, .et al. Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia, Sci Rep, 2017, 7: 1578 PMID: 28484277
Biological Activity
Dabrafenib is a potent and selective inhibitor of B-RAF protein kinase carrying V600E mutation, currently in clinical trial.
Targets
| B-Raf (V600E) (Cell-free assay) | B-Raf (Cell-free assay) | C-Raf (Cell-free assay) | ||
| 0.8 nM | 3.2 nM | 5.0 nM |
| In vitro (25°C) | DMSO | 30 mg/mL (57.74 mM) | |
| Water | <1 mg/mL (<1 mM) | ||
| Ethanol | <1 mg/mL (<1 mM) | ||
| In vivo | 30% PEG400/0.5% Tween80/5% propylene glycol | 8 mg/mL | |
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 19.25 mL | 96.23 mL | 192.46 mL |
| 0.5 mM | 3.85 mL | 19.25 mL | 38.49 mL |
| 1 mM | 1.92 mL | 9.62 mL | 19.25 mL |
| 5 mM | 0.38 mL | 1.92 mL | 3.85 mL |
*The above data is based on the productmolecular weight 519.6 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Catalog Num | A11381 |
|---|---|
| Actions | Inhibitor |
| M. Wt | 519.6 |
| Formula | C23H20F3N5O2S2 |
| Solubility | DMSO |
| Purity | >98% |
| Storage | at -20°C 3 years Powder |
| CAS No. | 1195765-45-7 |
| Synonyms | GSK2118436A |
| SMILES | CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F |
Datasheet
Product Tags
Product Questions
Product Questions
No Questions
You may also be interested in the following product(s)
Regorafenib (BAY 73-4506)
Regorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. Regorafenib (BAY 73-4506) is an ora…
TAK-632
TAK-632 is a potent pan-RAF inhibitor with favorable in vitro activity (BRAF(V600E) IC50, 2.4 nM; BRAF(wt), 8.3 nM; CRAF, 1.4 nM; pMEK (A37…
ZM 336372
ZM 336372 is a potent ATP-competitive inhibitor of Raf-1 in vitro (IC50 = 70 nM) with the paradoxical effect of inducing >100-fold activatio…
Dabigatran ethyl ester
Dabigatran ethyl ester, which is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity.
LGX 818 (Encorafenib)
LGX818 is an orally available Raf kinase inhibitor with potential antineoplastic activity.
AZ628
AZ628 is a RAF inhibitor with IC50 values: ca 30 nM for BRAF V600E and wild-type CRAF and 100 nM for wild-type BRAF.
B-Raf-inhibitor 1
B-Raf inhibitor 1 is a potent and selective B-Raf inhibitor with cell IC50s of 0.31 uM and 2 nM for A375 proliferation and A375 p-ERK respec…
PF-04880594
PF-04880594 is an inhibitor of RAF with IC50 values of 0.19 nM/0.13 nM and 0.39 nM for BRAF/BRAFV599E and c-RAF, respectively.
Keywords:buy Dabrafenib (GSK2118436A) | Dabrafenib (GSK2118436A) Supplier | purchase | cost | manufacturer | order | distributor | buy 1195765-45-7| 1195765-45-7 Supplier | purchase 1195765-45-7 | 1195765-45-7 cost | 1195765-45-7 manufacturer | order 1195765-45-7 | 1195765-45-7 distributor
Adooq Quality Guarantee
We promise all products perform as described.